Allergy Therapeutics (AGY)

 

AGY Share PerformanceMore

52 week high31.00 13/04/17
52 week low17.25 26/09/16
52 week change 1.00 (3.81%)
4 week volume10,070,841 02/04/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Issue of Equity

RNS Number: 3752C Allergy Therapeutics PLC 13 April 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Issue of equity in respect of the exercise of warrants and options 13 April 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, announces the issue and allotment ofa total n...

Hardman Research: Development across portfolio

RNS Number: 5821B Allergy Therapeutics PLC 05 April 2017 Hardman Research: Progressive development across portfolio Progressive development across portfolio - AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a 'Named Patient' basis. Tr...

Broker Forecast - Numis issues a broker note on Allergy Therapeutics PLC

Numis today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and raised its price target to 4...

Interim Results for six months ended 31 Dec 2016

RNS Number: 8178A Allergy Therapeutics PLC 29 March 2017 Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will host a meeting and call for analysts to provide an update on the Group, followed by a Q&A session, at 0900 BST today. Dial-in details are: +44 (0) 1452 555566. Conference ID: 75062637. Allergy Therapeutics plc ("Allergy Th...

Allergy Therapeutics recruits first patient in birch pollen trial

Allergy Therapeutics has recruited the first patient in its phase III study designed to evaluate the efficacy and safety of its u...

First Patient in Pivotal Phase III Birch Study

RNS Number: 6158Z Allergy Therapeutics PLC 16 March 2017 Al l e r g y Th e r a p e u ti cs p l c (" A l l e r gy T he r a peu t i cs" or t he " C o m p a n y " ) First Patient Recruited in Pivotal Phase III Birch Immunotherapy B301 Study 16 March 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical company specialising in allergy vaccin...

Notice of Interim Results

RNS Number: 9163Y Allergy Therapeutics PLC 09 March 2017 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Group") Notice of Interim Results 9 March 2017 Allergy Therapeutics (AIM:AGY) , the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its interim results for the six months ended 31 December 2016 on Wedn...

Broker Forecast - Stifel issues a broker note on Allergy Therapeutics PLC

Stifel today reaffirms its buy investment rating on Allergy Therapeutics PLC (LON:AGY) and set its price target at 60p.

Fundamental DataMore

EPS-2.29
Dividend yield0 %

Equity Research (AGY)

hardman & co
Allergy Therapeutics plc
06/04/2017
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in EU only on a ‘Named Patient’...
Allergy Therapeutics plc
15/11/2016
InnovaDerma* (IDP.L) 107.5p £10.98m Strong news flow this week from the main market listed  UK developer of 'at-home' and clinically proven treatments for hair loss, hair care, self-...
hardman & co
Allergy Therapeutics plc
26/09/2016
AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in Europe only on a ‘Named...

Latest discussion posts More

  • Hardman note well worth reading, imo

    h p://hardmanandco.com/docs/default?]source/company?]docs/allergy?]therapeu cs?]documents/agy?]interim?]resultsupdate?] 5th?]april.pdf
    5-Apr-2017
    Baffler
  • Re: Interims TV Clips

    I nearly fell asleep the middle of this. Figures, stuff and more figures CL
    29-Mar-2017
    Chicken Lips
  • Interims TV Clips

    Morning Short TV clip following results announcement today: www.fmp-tv.co.uk/company/allergy-therapeutics-investors-video-and-news/
    29-Mar-2017
    Dino78

Users' HoldingsMore

Users who hold Allergy Therapeutics also hold..
LLOYDS GRP.26%
BP20%
SIRIUS MINERALS17%
BARCLAYS16%
GLAXOSMITHKLINE15%

Codes & Symbols

ISINGB00B02LCQ05
SymbolsAGY, LSE:AGY, AGY.L, AGY:LN, LON:AGY, XLON:AGY